DDInter1298 DDInter1676
Nisoldipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nisoldipine prevents calcium-dependent smooth muscle contraction and subsequent vasoconstriction. Nisoldipine may be used in alone or in combination with other agents in the management of hypertension.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Nisoldipine {u} (Compound) resembles {v} (Compound) Nimodipine
Nisoldipine {u} (Compound) resembles {v} (Compound) Amlodipine
Nisoldipine {u} (Compound) treats {v} (Disease) hypertension
Nisoldipine {u} (Compound) binds {v} (Gene) ABCB1
Nisoldipine {u} (Compound) upregulates {v} (Gene) HMOX1
Nisoldipine {u} (Compound) is included by {v} (Pharmacologic Class) Dihydropyridines
Nisoldipine {u} (Compound) downregulates {v} (Gene) CDC20
Nisoldipine {u} (Compound) causes {v} (Side Effect) Weight decreased
Nisoldipine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ticagrelor
Nisoldipine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Theophylline
Nisoldipine (Compound) resembles Nimodipine (Compound)
Nisoldipine (Compound) resembles Amlodipine (Compound)
Nisoldipine (Compound) treats hypertension (Disease)
Nisoldipine (Compound) binds ABCB1 (Gene)
Nisoldipine (Compound) upregulates HMOX1 (Gene)
Nisoldipine (Compound) is included by Dihydropyridines (Pharmacologic Class)
Nisoldipine (Compound) downregulates CDC20 (Gene)
Nisoldipine (Compound) causes Weight decreased (Side Effect)
Nisoldipine may cause a minor interaction that can limit clinical effects when taken with Ticagrelor
Nisoldipine may cause a minor interaction that can limit clinical effects when taken with Theophylline